ArticleNPJ vaccines2017
Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells.
Article in NPJ vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Knowledge mapping of DNGR-1 on dendritic cells in immunotherapy: a review and bibliometric study.Frontiers in immunology · 2026Pooled it
- mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.MedComm · 2026Review
- Hitting the hidden: arming the immune system for the next zoonotic coronavirus spillover.The Journal of clinical investigation · 2026Article
- Intranasal DC-targeting vaccine booster elicits durable and cross-clade protective immunity against sarbecoviruses in mice.The Journal of clinical investigation · 2026Article
- Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.NPJ vaccines · 2025Review
- Pyroptotic cell corpses are crowned with F-actin-rich filopodia that engage CLEC9A signaling in incoming dendritic cells.Nature immunology · 2025Article
- Single-shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad, durable and protective systemic and mucosal immunity in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Vaccination against neoantigens induced in cross-priming cDC1 in vivo.Cancer immunology, immunotherapy : CII · 2024Article
- Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses.Advanced healthcare materials · 2023Article
- Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design.Frontiers in immunology · 2023Review
- Single cell RNA sequencing reveals distinct clusters of Irf8-expressing pulmonary conventional dendritic cells.Frontiers in immunology · 2023Article
- Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.Human vaccines & immunotherapeutics · 2022Article
- Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.Journal of virology · 2022Article
- Status and Challenges for Vaccination against Avian H9N2 Influenza Virus in China.Life (Basel, Switzerland) · 2022Review
- A single-shot vaccine approach for the universal influenza A vaccine candidate M2e.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Review
- Contribution of Dendritic Cell Subsets to T Cell-Dependent Responses in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Development and characterization of influenza M2 ectodomain and/or hemagglutinin stalk-based dendritic cell-targeting vaccines.Frontiers in microbiology · 2022Article
- Vaccine adjuvants to engage the cross-presentation pathway.Frontiers in immunology · 2022Review
- Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting model antigens (Ags) to Clec9A on DC has been shown to induce, not only cytotoxic T cells, but also high levels of Ab. In fact, Ab responses against immunogenic Ag were effectively generated even in the absence of DC-activating adjuvants. Here we tested if targeting weakly immunogenic putative subunit vaccine Ags to Clec9A could enhance Ab responses to a level likely to be protective. The proposed "universal" influenza Ag, M2e and the enterovirus 71 Ag, SP70 were linked to anti-Clec9A Abs and injected into mice. Targeting these Ags to Clec9A greatly increased Ab titres. For optimal responses, a DC-activating adjuvant was required. For optimal responses, a boost injection was also needed, but the high Ab titres against the targeting construct blocked Clec9A-targeted boosting. Heterologous prime-boost strategies avoiding cross-reactivity between the priming and boosting targeting constructs overcame this limitation. In addition, targeting small amounts of Ag to Clec9A served as an efficient priming for a conventional boost with higher levels of untargeted Ag. Using this Clec9A-targeted priming, conventional boosting strategy, M2e immunisation protected mice from infection with lethal doses of influenza H1N1 virus.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.